Filing Flows › Karyopharm Therapeutics (KPTI) › How it makes money
How Karyopharm Therapeutics (KPTI) makes money
Karyopharm Therapeutics (KPTI) made $33.4M of revenue in the second quarter 2026 (Q2 2026), -12% from a year earlier. Product brought in $30.8M (92%); License and Other brought in $2.7M (8%).
Drawing the Sankey…
Revenue by segment, Q2 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Product | $30.8M | 92.1% | +6% | +4% |
| License and Other | $2.7M | 7.9% | -55% | -68% |
Where each dollar of revenue goes
| Line | Q2 2026 | % of revenue |
|---|---|---|
| Revenue | $33.4M | 100.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q2 2026 | $33.4M | -12% |
| Q1 2026 | $35.1M | +17% |
| Q4 2025 | $34.1M | +12% |
| Q3 2025 | $44.0M | +14% |
| Q2 2025 | $37.9M | -11% |
| Q1 2025 | $30.0M | -9% |
| Q4 2024 | $30.5M | -10% |
From Karyopharm Therapeutics' 10-Q filed Aug 13, 2026 (on EDGAR).
Questions
How does Karyopharm Therapeutics make money?
Karyopharm Therapeutics (KPTI) made $33.4M of revenue in the second quarter 2026 (Q2 2026), -12% from a year earlier. Product brought in $30.8M (92%); License and Other brought in $2.7M (8%).
What is Karyopharm Therapeutics' biggest business?
Product: $30.8M in the second quarter 2026, 92% of revenue, +4% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.